Citations

Clear

499 citation(s) found for "Tracy, PB".

Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans
Kellerman, Donald , Kori, Shashidhar, Forst, Amy, Chang, Jen-Chih, Febbraro, Simone , WuTann, L, Thomas, Tracy, Taylor, Glyn , Dodick, DW

Mayo Clinic

Cephalalgia | December 16, 2011 | Volume: 32 | Issue: 2 | Pages: 150-158

10.1177/0333102411432299 | PMID 22174351 Get It

Background: Dihydroergotamine (DHE), a proven migraine treatment, currently has product labeling warning against concomitant use of CYP3A4 inhibitors because of potential drug interactions. However, no reported studies of such interactions with DHE administered by any route are available. Methods: The pharmacokinetics (PK) of MAP0004, an investigative inhaled DHE formulation, were assessed in human subjects with and without CYP3A4 inhibition by ketoconazole to evaluate the potential for drug interaction, elevation of DHE levels, and increased adverse effects. Results: After MAP0004 alone vs. MAP0004 plus ketoconazole, the DHE maximum concentrations (C max ) and area-under-the-curve (AUC 0–48 and AUC 0–∞ ) were not statistically significantly different nor was the C max of the primary metabolite, 8’-OH-DHE. A difference in 8’-OH-DHE AUCs was observed between MAP0004 with and without ketoconazole; however, the concentrations were very low. MAP0004 was well tolerated after both treatments. Conclusions: This study demonstrated that CYP3A4 inhibition had little to no effect on DHE PK after MAP0004 administration, apparently because of its high systemic and low gastrointestinal bioavailability. CYP3A4 inhibition slowed elimination of the metabolite 8’-OH-DHE, but concentrations were too low to be pharmacologically relevant.
Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium
Chan, Chi-Chao, Rubenstein, James L. , Coupland, Sarah E. , Davis, Janet L. , Johnston, Patrick B. , Cassoux, Nathalie , Touitou, Valérie , Smith, Justine R. , Batchelor, Tracy T. , Pulido, José S. , Harbour, J. William , Smith, Justine

Mayo Clinic

The Oncologist | November 1, 2011 | Volume: 16 | Issue: 11 | Pages: 1589-1599

10.1634/theoncologist.2011-0210 | PMID 22045784 Get It

Abstract Primary vitreoretinal lymphoma (PVRL), also known as primary intraocular lymphoma, is a rare malignancy typically classified as a diffuse large B-cell lymphoma and most frequently develops in elderly populations. PVRL commonly masquerades as posterior uveitis and has a unique tropism for the retina and central nervous system (CNS). Over 15% of primary CNS lymphoma patients develop intraocular lymphoma, usually occurring in the retina and/or vitreous. Conversely, 65%–90% of PVRL patients develop CNS lymphoma. Consequently, PVRL is often fatal because of ultimate CNS association. Current PVRL animal models are limited and require further development. Typical clinical findings include vitreous cellular infiltration (lymphoma and inflammatory cells) and subretinal tumor infiltration as determined using dilated fundoscopy, fluorescent angiography, and optical coherent tomography. Currently, PVRL is most often diagnosed using both histology to identify lymphoma cells in the vitreous or retina and immunohistochemistry to indicate monoclonality. Additional adjuncts in diagnosing PVRL exist, including elevation of interleukin-10 levels in ocular fluids and detection of IgH or T-cell receptor gene rearrangements in malignant cells. The optimal therapy for PVRL is not defined and requires the combined effort of oncologists and ophthalmologists. PVRL is sensitive to radiation therapy and exhibits high responsiveness to intravitreal methotrexate or rituximab. Although systemic chemotherapy alone can result in high response rates in patients with PVRL, there is a high relapse rate. Because of the disease rarity, international, multicenter, collaborative efforts are required to better understand the biology and pathogenesis of PVRL as well as to define both diagnostic markers and optimal therapies.
Predicting superficial venous incompetence with strain gauge plethysmography
Kalsi, H., Wysokiński, Waldemar E. , Heaser, Tracy V., Wennberg, Paul W. , Skeik, Nedaa , Wysokinski, Waldemar

Mayo Clinic

Phlebology: The Journal of Venous Disease | September 6, 2011 | Volume: 27 | Issue: 3 | Pages: 135-140

10.1258/phleb.2011.011001 | PMID 21893550 Get It

Background With currently available effective interventional methods to treat superficial venous insufficiency, it becomes particularly important to have a simple and reliable method to evaluate the location and severity of venous reflux. To date, there are few studies that evaluated plethysmography with and without tourniquet application to differentiate superficial from deep venous incompetence. Objectives To determine if strain gauge plethysmography (SGP) with and without tourniquet application can be used to distinguish between the superficial and deep venous components of venous incompetence. Methods We conducted a prospective study using SGP with and without tourniquet application and duplex ultrasound (duplex US) to assess the severity and location of venous incompetence in 62 patients (85 limbs, 42 women, with an age range of 32–81 years) referred to our vascular laboratory for haemodynamic evaluation. Based on duplex US results, patients were diagnosed with superficial (SVI), deep and superficial (mixed) and deep vein incompetence (DVI). Results Mixed incompetence was the most common type. Twenty-three out of 33 limbs in the SVI group normalized their refill rate (RR) with tourniquet application (69.6%). Normalization of the RR with tourniquet application was less common in the mixed ( n: 17 out of 40, 42.5%) and DVI ( n: 2 out of 6, 33.3%) groups. Conclusion SGP with tourniquet application is a simple and fast technique that can identify patients with SVI, based on RR improvement, who probably would benefit more from ablation procedures. Further studies evaluating impact of SGP with tourniquet test results on clinical outcome of SVI invasive treatment are warranted
Cardiac Sympathetic Reserve and Response to Cardiac Resynchronization Therapy
Cha, Yong‐Mei , Dong, Ying-Xue, Kemp, Bradley J. , Oh, Jae K. , Miyazaki, Chinami , Hayes, David L. , Rea, Robert F., Asirvatham, Samuel J. , Webster, Tracy L., Dalzell, Connie, Hodge, David O. , Herges, Regina M., Yong, Yan-zhong, Zhang, Yanhua, Chen, Peng‐Sheng , Chareonthaitawee, Panithaya , Zhang, Yanhua, Asirvatham, Samuel J

Mayo Clinic

Circulation: Heart Failure | March 19, 2011 | Volume: 4 | Issue: 3 | Pages: 339-344

10.1161/circheartfailure.110.959858 | PMID 21421772 Get It

Background— The objective of the present study was to investigate the effect of cardiac resynchronization therapy (CRT) on cardiac autonomic function. Methods and Results— This prospective study included 45 consecutive patients with heart failure who received CRT devices with defibrillator and 20 age-matched, healthy control subjects. At baseline and 3 months and 6 months after CRT, we assessed New York Heart Association (NYHA) class, 6-minute walk distance, plasma sympathetic biomarker nerve growth factor, echocardiography, heart rate variability and cardiac presynaptic sympathetic function determined by iodine 123 metaiodobenzylguanidine scintigraphy. After CRT, NYHA class improved by 1 class ( P <0.001), and left ventricular ejection fraction increased by 8% ( P <0.001). Along with improvement in the standard deviation of all normal-to-normal R-R intervals (85.63±31.66 ms versus 114.79±38.99 ms; P =0.004) and the standard deviation of the averaged normal-to-normal R-R intervals (82.62±23.03 ms versus 100.50±34.87 ms; P =0.004), the delayed heart/mediastinum (H/M) ratio increased (1.82 [0.58] versus 1.97 [0.59]; P =0.03), whereas the mean (SD) H/M washout rate was reduced (48% [19%] versus 37% [22%]; P =0.01). Twenty-two of 45 study patients responded to CRT, with a reduction of left ventricular end-systolic volume index >15%. Compared with nonresponders, responders had a higher delayed H/M ratio (2.11 versus 1.48; P =0.003) and lower H/M washout rate (37% versus 62%; P =0.003) at baseline. Conclusions— CRT improved sympathetic function. Cardiac sympathetic reserve may be a marker for the reversibility of failing myocardial function.
Primary CNS Lymphoma in Children and Adolescents: A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)
Abla, Oussama , Weitzman, Sheila, Blay, Jean‐Yves , Abrey, Lauren E. , Neuwelt, Edward A. , Doolittle, Nancy D., Baehring, Joachim M. , Pradhan, Kamnesh R. , Martin, Sheelagh, Guerrera, Michael F., Shah, Shafqat, Ghesquières, Hervé , Silver, Michael, Batchelor, Tracy T. , O’Neill, Brian Patrick , Betensky, Rebecca A. , Blay, Jean-Yves

Mayo Clinic

Clinical Cancer Research | January 12, 2011 | Volume: 17 | Issue: 2 | Pages: 346-352

10.1158/1078-0432.ccr-10-1161 | PMID 21224370 Get It

Abstract Purpose: To describe the demographic and clinical features and outcomes for children and adolescents with primary CNS lymphoma (PCNSL). Experimental Design: A retrospective series of children and adolescents with PCNSL was assembled from 10 cancer centers in 3 countries. Results: Twenty-nine patients with a median age of 14 years were identified. Sixteen (55%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 1 or greater. Frontline therapy consisted of chemotherapy only in 20 patients (69%), while 9 (31%) had chemotherapy plus cranial radiotherapy. Most patients received methotrexate (MTX)-based regimens. Overall response rate was 86% (complete remission 69%, partial remission 17%). The 2-year progression-free survival (PFS) and overall survival (OS) rates were 61% and 86%, respectively; the 3-year OS was 82%. Univariate analyses were conducted for age (≤14 vs. &gt;14 years), PS (0 or 1 vs. &gt;1), deep brain lesions, MTX dose, primary treatment with chemotherapy alone, intrathecal chemotherapy, and high-dose therapy. Primary treatment with chemotherapy alone was associated with better overall response rates with an odds ratio (OR) of 0.125 (P = 0.02). There was a marginally significant relationship between higher doses of MTX and response (OR = 1.5, P = 0.06). ECOG-PS of 0 to 1 was the only factor associated with better outcome with hazard ratios of 0.136 (P = 0.017) and 0.073 (P = 0.033) for PFS and OS, respectively. Conclusion: This is the largest series collected of pediatric PCNSL. The outcome of children and adolescents seems to be better than in adults. PS of 0 to 1 is associated with better survival. Clin Cancer Res; 17(2); 346–52. ©2011 AACR.
Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease
Blazer‐Yost, Bonnie L. , Haydon, Julie, Eggleston‐Gulyas, Tracy, Chen, Jey‐Hsin, Gattone, Vincent H., Wang, Xiaofang , Torres, Vicente E.

Mayo Clinic

PPAR Research | November 1, 2010 | Volume: 2010 | Issue: No issue available | Pages: 1-8

10.1155/2010/274376 | PMID 21052534 Get It

Polycystic kidney disease (PKD) is a genetic disorder characterized by growth of fluid-filled cysts predominately in kidney tubules and liver bile ducts. Currently, the clinical management of PKD is limited to cyst aspiration, surgical resection or organ transplantation. Based on an observation that PPAR γ agonists such as pioglitazone and rosiglitazone decrease mRNA levels of a Cl − transport protein, CFTR (cystic fibrosis transmembrane conductance regulator), and the Cl − secretory response to vasopressin in cultured renal cells, it is hypothesized that PPAR γ agonists will inhibit cyst growth. The current studies show that a 7- or 14-week pioglitazone feeding regimen inhibits renal and hepatic bile duct cyst growth in the PCK rat, a rodent model orthologous to human PKD. These studies provide proof of concept for the mechanism of action of the PPAR γ agonists and suggest that this class of drugs may be effective in controlling both renal and hepatic cyst growth and fibrosis in PKD.
Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: A study of sources of variation in assay results
Andrianorivo, Aurelie, Riggs, B. Lawrence, Mann, Kenneth G. , Tracy, Russell P.

Mayo Clinic

Journal of Bone and Mineral Research | February 24, 2010 | Volume: 5 | Issue: 5 | Pages: 451-461

10.1002/jbmr.5650050506 | PMID 2368627 Get It

Abstract We have compared two assays for osteocalcin (BGP, bone gla protein), one based on a monoclonal antibody, the other based on a polyclonal serum, in an effort to better understand the factors that contribute to the wide variation reported for osteocalcin normal ranges. The two assays compared well using serum samples, with a correlation coefficient of 0.9071 (n = 48). However, the monoclonal antibody assay returns values increased over the polyclonal assay by approximately 1.5-fold. Gel permeation studies indicate that these larger values are due primarily to increased reactivity in the monoclonal assay with high- and low-molecular-weight forms of osteocalcin in plasma; both assays give similar reactions to intact osteocalcin. Analysis of samples from individuals with increased bone resorption due to parathyroid hormone administration reveals that the decrease seen in osteocalcin values after hormone infusion occurs primarily in the fraction that corresponds to intact osteocalcin. During the course of these studies, we re-evaluated the extinction coefficient for osteocalcin, arriving at the value E = 1.33 mg/ml−1, cm−1. We also observed a significant negative interference in both assays (and a commercial assay) caused by hemolysis. This interference is due to proteolysis of osteocalcin by enzymatic activity released from the lysed red cells.
Evidence-Based Systematic Review: Effects of Nonspeech Oral Motor Exercises on Speech
McCauley, Rebecca J. , Lof, Gregory L., Schooling, Tracy, Frymark, Tobi , Strand, Edythe A.

Mayo Clinic

American Journal of Speech-Language Pathology | November 1, 2009 | Volume: 18 | Issue: 4 | Pages: 343-360

10.1044/1058-0360(2009/09-0006) | PMID 19638484 Get It

PurposeThe purpose of this systematic review was to examine the current evidence for the use of oral motor exercises (OMEs) on speech (i.e., speech physiology, speech production, and functional speech outcomes) as a means of supporting further research and clinicians' use of evidence-based practice.MethodThe peer-reviewed literature from 1960 to 2007 was searched for articles examining the use of OMEs to affect speech physiology, production, or functional outcomes (i.e., intelligibility). Articles that met selection criteria were appraised by 2 reviewers and vetted by a 3rd for methodological quality, then characterized as efficacy or exploratory studies.ResultsFifteen studies met inclusion criteria; of these, 8 included data relevant to the effects of OMEs on speech physiology, 8 on speech production, and 8 on functional speech outcomes. Considerable variation was noted in the participants, interventions, and treatment schedules. The critical appraisals identified significant weaknesses in almost all studies.ConclusionsInsufficient evidence to support or refute the use of OMEs to produce effects on speech was found in the research literature. Discussion is largely confined to a consideration of the need for more well-designed studies using well-described participant groups and alternative bases for evidence-based practice.